|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Lactate and MCTs, especially MCT1 and MCT4, are important contributors to tumor aggressiveness.
|
31395464 |
2020 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Candidate inhibitors 1-9 have been evaluated for <i>in vitro</i> cell proliferation against MCT1 and MCT4 expressing cancer cell lines.
|
31040927 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In vivo <sup>13</sup> C MRSI studies of orthotopic tumors in mice also showed a significant 52% decrease in hyperpolarized [1-<sup>13</sup> C]Lac/Pyr when comparing vorinostat-treated U87 GBM tumors with controls, and, as in the cell studies, this metabolic finding was associated with increased MCT1 and MCT4 expression in HDAC-inhibited tumors.
|
30561869 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Monocarboxylate transporters 1 and 4 (MCT1 and MCT4) are involved in tumour development and progression.
|
31827199 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The results indicate the MCT4-inhibition-induced disruption of tumor intracellular pH holds promise as a therapy against not only HCC, but a broader spectrum of MCT4-overexpressing hyperglycolytic tumors.
|
31479685 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
MCT1 may serve as a target to treat NHL (diffuse large B cell lymphoma) patients with high MCT1/low MCT4 expressing tumours.
|
30790227 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Monocarboxylate transporters 1 and 4 (MCT1 and MCT4) are involved in tumor development and progression.
|
31017677 |
2019 |
|
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Candidate inhibitors 1-9 have been evaluated for <i>in vitro</i> cell proliferation against MCT1 and MCT4 expressing cancer cell lines.
|
31040927 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
High MCT4 levels in HNSCC have been associated with poor prognosis, but the role of MCT4 in the development and progression of this cancer is still poorly understood.
|
30211114 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Monocarboxylate transporter-4 (MCT4), a monocarboxylic acid transporter, demonstrates significantly increased expression in the majority of malignancies.
|
30051648 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Dual Inhibition of the Lactate Transporters MCT1 and MCT4 Is Synthetic Lethal with Metformin due to NAD+ Depletion in Cancer Cells.
|
30540938 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Given the relationships between MCT1 and MCT4 and cancer, they offer a unique opportunity for novel treatment strategies.
|
30416849 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The NP technology can modulate the glycolysis pathway by silencing MCT4 to induce tumor cell acidosis, and concurrently exacerbate oxidative stress in tumor cells via the Fenton-like reaction.
|
29276823 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Objective Many aggressive head and neck cancers contain 2 metabolically coupled tumor compartments: a glycolytic stromal compartment with low caveolin-1 (CAV1) and high monocarboxylate transporter 4 (MCT4) expression and a highly proliferative carcinoma cell compartment with high MCT1.
|
29232177 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In summary, using the expression of MCT4 and GLUT1 and their metabolic parameters to determine the metabolic status of tumors is promising for predicting the prognosis of patients with HCC.
|
30306706 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This work reveals that different types of net acid extruding transporters, NHE1, NBCn1 and MCT4, are frequently expressed in patient mammary tumor tissue and demonstrates for the first time that they promote growth of TNBC human mammary tumors in vivo via distinct but overlapping mechanisms.
|
29363134 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
High expression of MCT1 and MCT4 in tumour tissues was associated with poor patient outcome; further the correlation between MCT1 expression and poor prognosis in breast cancer was further strengthened when combined with MCT4 overexpression in the adjacent adipose tissue.
|
29775610 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Inhibition of MCT4 results in decreased tumor growth <i>in vitro</i> and <i>in vivo</i> Targeting lactate metabolism via MCT4 therefore provides a promising therapeutic approach for invasive urothelial carcinoma, especially in the basal subtype.
|
30262589 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Interestingly, a glycolytic tumor environment, as determined by the expression of MCT4 in the tumor stroma, was associated with the immune evasive environment and poor prognosis.
|
28984302 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Additionally, diffusion-weighted HP <sup>13</sup>C pyruvate MRI showed that the A498 tumors had significantly higher <sup>13</sup>C lactate apparent diffusion coefficients compared to 786-O tumors, with corresponding higher MCT4 expression, which likely reflects more rapid lactate export in the A498 tumors.
|
30189677 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Together, these data suggest that the key effect of MCT4 depletion on NK cells probably utilizes inductive autophagy as a compensatory metabolic mechanism to minimize the acidic extracellular microenvironment associated with lactate export in tumors.
|
30051648 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, we found MCT4 positive macrophages within the tumor and in the stroma surrounding the lesions in both human samples of HNSCC and in the 4NQO treated animals.
|
30211114 |
2018 |
|
Adolescent idiopathic scoliosis
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
The coexistence of copy number variations (CNVs) and single nucleotide polymorphisms (SNPs) at a locus can result in distorted calculations of the significance in associating SNPs to disease.
|
30019117 |
2018 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Given the relationships between MCT1 and MCT4 and cancer, they offer a unique opportunity for novel treatment strategies.
|
30416849 |
2018 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Dual Inhibition of the Lactate Transporters MCT1 and MCT4 Is Synthetic Lethal with Metformin due to NAD+ Depletion in Cancer Cells.
|
30540938 |
2018 |